Somatic mutations in cancer cells can generate tumour-specific neoepitopes, which are
recognized by autologous T cells in the host. As neoepitopes are not subject to central …

Recent advances in cancer treatment have emerged from new immunotherapies targeting T-
cell inhibitory receptors, including cytotoxic T-lymphocyte associated antigen (CTLA)-4 and …

CD8+ T cell–dependent killing of cancer cells requires efficient presentation of tumor
antigens by human leukocyte antigen class I (HLA-I) molecules. However, the extent to …

Harnessing the immune system to eradicate malignant cells is becoming a most powerful
new approach to cancer therapy. FDA approval of the immunotherapy-based drugs …

Neoantigens are antigens encoded by tumor-specific mutated genes. Studies in the past few
years have suggested a key role for neoantigens in cancer immunotherapy. Here we review …

Studies of the administration of interleukin-2 to patients with metastatic melanoma or kidney
cancer have shown that immunological manipulations can mediate the durable regression …

The technological advances occurred in the last few years have led to a great increase in
the number of tumor associated antigens (TAA) that are currently available for clinical …

Cancer genome sequencing has enabled the rapid identification of the complete repertoire
of coding sequence mutations within a patient's tumor and facilitated their use as …

Since the cloning of MAGE-1 [125], the first gene reported to encode a human tumor antigen
recognized by T cells, molecular identification and characterization of tumor antigens has …

Many human tumor-associated antigens (TAAs) have recently been identified and
molecularly characterized. When bound to major histocompatibility complex molecules, TAA …